Analyst upgrades:

• Collins Stewart upgraded General Dynamics (NYSE: GD) to Buy from Hold as it finds the valuation compelling at current levels and sees potential upside from a better economy and better-than-expected defense budgets.
• SunTrust views the sell-off in shares of Cabot Oil (NYSE: COG) as a buying opportunity and expects the Pennsylvania Department of Environmental Protection order to be resolved quickly. The firm upgraded Cabot to Buy from Neutral.
• Barclays upgraded Cisco (NASDAQ: CSCO) to Overweight from Equal Weight based on expectations for improved carrier demand, continued U.S. momentum, and an improved Europe.
• Applied Materials (NASDAQ: AMAT) was upgraded to Buy from Hold at Citigroup.
• Stericycle (NASDAQ: SRCL) was upgraded to Gradually Accumulate from Hold at Soleil.
• Grupo Televisa (NYSE: TV) was upgraded to Neutral from Sell at Goldman.

I keep watching Marvel Entertainment (NYSE: MVL), waiting (or maybe "hoping" would be the better term) for a great pullback to get in on the action. I never seem to get it. Who knows, maybe it'll happen later today. But as of Tuesday's close, Marvel was still above $40 per share after dropping less than 1%. And that was after the traders digested the company's Q2 earnings report. That, in my opinion, is telling.

Marvel has always been the kind of stock that can throw you for a loop. I know, because I've owned it before. Is it me, or is the market getting increasingly comfortable with the company's business model of taking risk in the movie industry? Maybe it's too early to tell. At any rate, according to the press release, Marvel saw big decreases in both sales and per-share income. The top line dropped 26%, while the bottom line fell 37% to 37 cents per share. Marvel beat earnings estimates by 6 cents per share according to Reuters.

Analyst upgrades:

• Thomas Weisel upgraded SanDisk (NASDAQ: SNDK) to Overweight from Market Weight due to accelerating manufacturing cost declines, potential NAND flash sourcing upside at Toshiba (OTC: TOSBF) and Samsung and an increase in 2H09 demand.
  
• Oppenheimer upgraded Quality Systems (NASDAQ: QSII) to Perform from Underperform to reflect potential benefits from the stimulus package and channel checks that indicated IT budgets are stabilizing. The firm raised its target price on shares to $54 from $40.
  
• RBC Capital upgraded OSI Pharmaceuticals (NASDAQ: OSIP) to Outperform from Sector Perform following positive Tarceva survey results and cites valuation.
• Marriott (NYSE: MAR) was upgraded to Outperform from Market Perform at JMP Securities.
  
• Grainger (NYSE: GWW) was upgraded to Buy from Neutral at BofA/Merrill.
  
• Duncan Energy Partners (NASDAQ: DEP) was upgraded to Buy from Neutral at UBS.

Thoratec (NASDAQ: THOR), known for its ventricular assist devices (VADs) for patients suffering late-stage heart failure, recently bought Australia's HeartWare. Investors responded positively to this move because it brings new technology to Thoratec and expands the company's already significant market share.

THOR currently has 85% of the U.S. heart pump market and 65% of Europe's, and this new technology could ensure THOR stays on the top of this market for at least the next five to 10 years. The Thoratec-HeartWare partnership has the potential to grow into a multibillion-dollar business, which will translate to big sales and earnings growth.

Small-cap stocks are a GREAT place to start if you're serious about rebuilding your wealth and securing your financial future.

But what makes small-cap stocks so spectacular?

The bear market stripped analysts from small stocks -- hardly anyone is covering them anymore. This creates wonderful pricing anomalies and gives the individual investor a significant edge.

Marvel Entertainment (NYSE: MVL), whose colleagues include Sony (NYSE: SNE), News Corp. (NASDAQ: NWS), and Viacom (NYSE: VIA), issued its first-quarter report on Tuesday.

The market liked what it saw. That's because the comic-book concern beat analyst estimates by a pretty significant margin. Hey, what else would you expect from the company that brought you Iron Man?

Marvel delivered 57 cents per share in income. According to analysts, Wall Street was hoping for 37 cents per share. Quite a surprise.

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Marvel (NYSE: MVL) is a great company. It's got a lot of cool characters in its vast comic book portfolio. Spider-Man, Hulk, X-Men, you know them all. And it's a fun stock to both invest in and trade. It's a more direct play on movies than a Disney (NYSE: DIS) or a Time Warner (NYSE: TWX) is. I've made money on Marvel in the past. I don't currently own it, so I was pretty interested when I heard that Wedbush Morgan issued an upgrade this week.

Wedbush Morgan basically said that the market is undervaluing Marvel's potential. It sees a price target of $31. I myself think Marvel will break $30 yet again, but the problem I have is with sentiment. Exactly how will the market react to Marvel's shares this year?

So, I'm still trying to figure out a strategy for the coming year for my portfolio. Stocks are starting to feel a little better to me, but I'm very, very cautious about timing in terms of trades. For instance, I'd rather wait until we see a substantial pullback from the recent rally before taking some of my cash on the sidelines and putting it to work. But I've got two ideas in the movie sector that I'm looking at: DreamWorks Animation (NYSE: DWA) and Marvel Entertainment (NYSE: MVL).

First off, both are great companies. No, not every move they make is perfect (example: Marvel still can't properly monetize its Incredible Hulk property with a decent film). But both stocks have held up relatively well, in my opinion, during the financial implosion. Both stocks are also below their respective 52-week high's and above their respective 52-week low's. That's not a bad position to be in (although I should point out that I generally would like to get these two around their 52-week low's). But which stock has the edge?

Well, Marvel's shares have been strong lately. According to the AOL quote at the time of this writing, Marvel is in the green in all time frames (year-to-date, one-month, one-year, etc.). DreamWorks Animation is in the red in a couple spots, but for the most part, it's been performing somewhat similarly to Marvel. I don't really see that much of a difference in terms of strength. Plus, both are arguably essentially equal in terms of valuation (at least in my opinion).

Well, I've finally done it. I sold my entire position of Marvel Entertainment (NYSE: MVL). It wasn't an easy decision.

When I covered Marvel's latest earnings report, I alluded to the issue of emotion. My emotion, to be specific. I stated that it most likely would be in my best interest to get out of the stock since there really weren't many catalysts coming up in 2009 to propel the stock higher.

In fact, it would be easy to make the argument that, since the market has been so haywire and irrational, one must take profits when one has a profit to indeed take. Marvel is just such a stock in my portfolio. I have several paper losses, but Marvel retains its green status on my board. I love the company's story on a long-term basis, absolutely adore it, but I think it is incumbent upon every trade and investor to build a cash stash that can be used for opportunities the market may throw their way.

The Marvel position that I liquidated on Tuesday was one I owned for quite a while. It had a nice profit attached to it. I feel good about preserving that capital, especially since Marvel is lower today (at least, it's lower as I write this; as we all know, that could change in a heartbeat).

Today ended up being another one of those days that almost could have been special. Despite futures being lower all morning after the Asian markets slid into oblivion with Japan at 26-year lows, U.S. markets recovered on less-bad housing sale data and an S&P report that said the Christmas of 2008 shopping season may only be flat compared to 2008. Both were bad, but very acceptable for the current poor sentiment. Unfortunately, late day selling from redemptions and the "re-emergence of fears" took hold.

Here are today's unofficial closing bell levels:
52-WEEK LOWS
Top 10 Analyst Calls
Technology Sector Upgrades

Dillard's Inc. (NYSE: DDS) was up over 30% at $4.48 in today's final minutes of trading. Management bought shares and insiders want new management.

Humana (NYSE: HUM) almost didn't make sense as far as the trader reaction to earnings is concerned. The health insurer posted earnings at $1.49 EPS vs. estimates of $1.47 and gave guidance of $1.00 to $1.10 after a $0.10 item vs. $1.20 estimates. For 2009, it sees earnings at $5.90 to $6.10 vs. $5.85 EPS estimates. That gives a forward P/E ratio of under 7, yet shares were down 14% at $31.12 right before the close of trading.

According to The Hollywood Reporter, comic-book publisher Marvel (NYSE: MVL) has come up with another character set to exploit from its vast library. I've never heard of this title, but apparently a comic book called Runaways, which has been around since 2002 and has developed a following. It has been tapped by management to be source material for a movie. It has something to do with teenagers who have parents that are evil villains. This sends them for a loop, causing them to run away and to attempt to process this shock to their systems. I don't really know a lot about this universe.

And that's what fascinates me about it from the perspective of being a shareholder. It both frightens and excites me at the same time. One of the biggest issues surrounding Marvel has been the oft-mentioned value of the company's 5,000 characters. Some have pointed out that, once you get through Hulk, X-Men, Spider-Man ,Iron Man and a few of the other major hitters, Marvel really doesn't have any other big properties to lean on in terms of generating viable movie franchises. For instance, is Ant-Man going to be a huge success at the movies? For that matter, what the heck is an Ant-Man anyway? Wasn't he made fun of in an old Saturday Night Live sketch from the 1970's? I sometimes do have some reticence when thinking about characters such as Thor, Captain America, and, yes, Ant-Man. Will they be accepted by the movie-going youth as readily as Iron Man recently was at the multiplex?

This is why I think it's a neat idea to start testing the perception of Wall Street investors by announcing the film adaptation of a lesser-known quantity. I mean, I haven't heard of this Runaways thing, at least. But maybe something a little more modern compared to the Captain America character will resonate perfectly fine with the youthful target audience of today. Perhaps Marvel will find out the true value of its brand equity when it slaps its name on something that hasn't been promoted over several decades. It's difficult to say at this stage, and I'll concede that it might be a bit early to begin evaluating this concept when investors are more worried at the moment over the potential success or failure of the new Hulk picture that is set to open very shortly.

Still, if Marvel wants to compete with big guns such as Disney (NYSE: DIS) and Time Warner (NYSE: TWX), then it needs to broaden its horizons and move beyond Wolverine.

MOST NOTEWORTHY: Mortgage Insurers, Thoratec Laboratories and Callaway Golf were today's noteworthy initiations:

• Keefe Bruyette resumed coverage of Old Republic (NYSE:ORI), MGIC Investment (NYSE:MTG), PMI Group (NYSE:PMI) and Radian (NYSE:RDN) with Market Perform ratings and a $16 target, $13 target, $7 target and $6.50 target, respectively, as they expect increased capital needs to generate operational headwinds in the near-term.
  
• JMP Securities expects FDA approval of Thoratec's (NASDAQ:THOR) next generation HeartMate II VAD any day now and for the company to meet/beat 2008 sales guidance. Shares were started with an Outperform rating and $20 target.
  
• Callaway Golf (NYSE:ELY) was assumed at Stephens with an Overweight rating and $19 target. The firm is positive on Callaway's leadership position, strong balance sheet, new products and international opportunity.

OTHER INITIATIONS:

• Kaufman Bros. initiated Bancscares of Florida (NASDAQ:BOFL) with a Buy rating and $15.50 target.
  
• Raymond James started Dialysis Corp of America (NASDAQ:DCAI) with a Strong Buy rating and $9 target.
  
• Intuitive Surgical (NASDAQ:ISRG) was initiated at Lazard with a Buy rating and $420 target.

MOST NOTEWORTHY: UBS AG, ProLogis, AMB Property, Navteq and PDL BioPharma were today's noteworthy upgrades:

• JP Morgan upgraded shares of UBS (NYSE: UBS) to Neutral from Underweight as they believe the company can start fresh after yesterday's pre-announcement.
  
• Banc of America upgraded shares of ProLogis (NYSE: PLD) and AMB Property (NYSE: AMB) to Buy from Neutral to reflect their positive outlook on global industrial REITs and believes they are positioned to benefit from global demand for industrial space.
  
• Navteq Corporation (NYSE: NVT) was upgraded at Deutsche Bank to Hold from Sell to reflect the acquisition by Nokia Corporation (NYSE: NOK).
  
• Wachovia raised shares of PDL BioPharma Inc (NASDAQ: PDLI) to Outperform from Market Perform following the CEO resignation and potential sale of the company.

OTHER UPGRADES:

• Thor Industries (NYSE: THO) was upgraded to Buy from Gradually Accumulate at Soleil.
  
• Gabelli upgraded Hershey Company (NYSE: HSY) to Hold from Sell.
  
• Forest Laboratories (NYSE: FRX) was upgraded at Citigroup to Hold from Sell.
  
• Roth Capital upgraded Conexant Systems (NASDAQ: CNXT) to Hold from Sell.

MOST NOTEWORTHY: BT Group, Luminent Mortage, Cognos, Thor Industries and Watson Pharmaceuticals were today's noteworthy upgrades:

• ING Group upgraded shares of BT Group (NYSE: BT) to Hold from Sell to reflect the company's more stable revenue trend and improving cash flow generation.
  
• Deutsche Bank upgraded shares of Luminent Mortgage Capital (NYSE: LUM) to Hold from Sell, as they believe the company's portfolio is beginning to stabilize and its liquidity has improved.
  
• Goldman upgraded Cognos Inc (NASDAQ: COGN) to Buy from Neutral following its Q2 report.
  
• Thor Industries (NYSE: THO) was raised to Sector Perform from Underperform at RBC Capital Markets. The firm's checks indicate strengthening backlog and lower promotional spending.
  
• Roth Capital believes Watson Pharmaceuticals (NYSE: WPI) is about to enter a growth phase with Paul Bisaro at the helm and is positive on Silodosin potential. The firm upgraded shares to Buy from Hold.

OTHER UPGRADES:

• Bank of the Ozarks (NASDAQ: OZRK) was upgraded to Buy from Neutral at B. Riley.
  
• Bear upgraded Harman International (NYSE: HAR) to Outperform from Market Perform.
  
• Goldman upgraded Packagaing Corporation (NYSE: PKG) and Smurfit-Stone Container (NASDAQ: SSCC) to Buy from Neutral.
  
• Friedman Billings raised Conseco Inc (NYSE: CNO) to Outperform from Market Perform.